Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis’ Xolair to receive NHS funding after NICE ruling

Novartis’ Xolair to receive NHS funding after NICE ruling

26th July 2013

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has ruled that its severe allergic asthma therapy Xolair should receive NHS funding.

Eligible patients including children aged six years and above will now encounter no barriers in receiving treatment with Xolair, which NICE states can offer life-changing benefits when used as an add-on to optimised standard therapy.

Xolair has been shown to be more clinically effective in treating severe persistent allergic asthma than optimised standard therapy alone, resulting in a reduction in hospital admissions in adults and children.

It is estimated that more than five million people in the UK suffer from asthma, with children comprising 1.1 million of this total.

Dr Robert Niven, senior lecturer for respiratory medicine at the University Hospital of South Manchester NHS Foundation Trust, said: "Many patients unnecessarily accept the everyday limitations and sudden asthma attacks, which are a feature of severe allergic asthma."

Earlier this month, the company's eye drug Lucentis received European regulatory approval as a treatment for visual impairment due to choroidal neovascularisation secondary to pathologic myopia.ADNFCR-8000103-ID-801617154-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.